Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $25.60 Average Target Price from Brokerages

Astria Therapeutics, Inc. (NASDAQ:ATXS) has earned a consensus recommendation of “Buy” from the six analysts that are presently covering the firm, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $25.60.

A number of brokerages have recently commented on ATXS. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Thursday, November 14th. Oppenheimer raised their target price on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Finally, Evercore ISI raised shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th.

Hedge Funds Weigh In On Astria Therapeutics

A number of large investors have recently bought and sold shares of ATXS. Quest Partners LLC grew its holdings in Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 3,112 shares during the last quarter. PDT Partners LLC purchased a new position in Astria Therapeutics in the third quarter worth $140,000. SG Americas Securities LLC purchased a new position in Astria Therapeutics in the third quarter worth $155,000. Hsbc Holdings PLC purchased a new position in Astria Therapeutics in the second quarter worth $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new position in Astria Therapeutics in the first quarter worth $200,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Stock Performance

Shares of NASDAQ:ATXS opened at $10.30 on Friday. The firm has a market cap of $581.27 million, a PE ratio of -4.93 and a beta of 0.71. The firm’s 50 day simple moving average is $11.23 and its 200-day simple moving average is $10.62. Astria Therapeutics has a one year low of $4.43 and a one year high of $16.90.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.